BioCardia (BCDA) vs Intensity Therapeutics (INTS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
BioCardia (BCDA) has outperformed Intensity Therapeutics (INTS) over the past year, losing 25.4% versus a loss of 48.4%. BioCardia is the larger company by market cap ($16.0 million vs $12.0 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BCDA | INTS |
|---|---|---|
| Share price | $1.06 | $3.68 |
| Market cap | $16.05M | $12.01M |
| 1-day change | -2.75% | -3.16% |
| YTD return | -15.20% | -64.10% |
| 1-year return | -25.35% | -48.35% |
| 5-year return | -97.59% | — |
| EPS (TTM) | $-0.64 | $-3.89 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.80 | $43.50 |
| 52-week low | $0.75 | $3.21 |
| Distance from 52-week high | -41.11% | -91.54% |
| Analyst consensus | none | none |
| Avg. price target upside | +1362.26% | +425.27% |
| Average volume | 282.05K | 25.93K |
| Shares outstanding | 15.14M | 3.26M |
| Employees | 17 | 5 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BCDA has outperformed INTS by 23.0 percentage points over the past year.
About BioCardia
BCDA stock →BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company's lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.
Healthcare · Biotechnology · 17 employees
About Intensity Therapeutics
INTS stock →Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer relapse and metastasis in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials.
Healthcare · Biotechnology · 5 employees
BCDA vs INTS FAQ
Which is bigger, BioCardia or Intensity Therapeutics?
BioCardia (BCDA) is larger, with a market capitalization of $16.05M compared with $12.01M for Intensity Therapeutics (INTS).
Which stock has performed better over the past year, BCDA or INTS?
BCDA returned -25.35% over the past 12 months, compared with -48.35% for INTS (price return, excluding dividends). Past performance does not predict future results.
Are BioCardia and Intensity Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.